Subtopic Deep Dive
Intraocular Chemotherapy for Retinoblastoma
Research Guide
What is Intraocular Chemotherapy for Retinoblastoma?
Intraocular chemotherapy for retinoblastoma delivers melphalan, topotecan, or carboplatin via intravitreal or ophthalmic artery routes to treat vitreous seeds and recurrent intraocular disease.
This approach targets advanced retinoblastoma cases previously managed with enucleation or radiotherapy. Key studies report 80-90% globe salvage rates using intra-arterial melphalan (Abramson et al., 2008, 475 citations). Over 20 papers since 2008 evaluate toxicity and efficacy endpoints.
Why It Matters
Intraocular chemotherapy enables eye preservation in 80-90% of advanced unilateral retinoblastoma cases, reducing enucleation rates (Abramson et al., 2008). It avoids radiotherapy complications like secondary cancers, improving quality of life (Gobin, 2011). Real-world applications include multicenter protocols for group D/E tumors, with Abramson et al. (2008) influencing global standards adopted in over 50 centers worldwide. Gallie (1996) demonstrated chemotherapy plus focal therapy cures intraocular disease without radiation in pilot cohorts.
Key Research Challenges
Ocular Toxicity Profiles
Intra-arterial melphalan causes retinal vascular changes and electroretinogram decline in 20-30% of cases (Abramson et al., 2008). Balancing dose for tumor control versus phthisis remains unresolved. Long-term visual outcomes average 20/200 or worse (Gobin, 2011).
Vitreous Seed Recurrence
Vitreous seeds persist post-treatment in 15-25% of advanced cases despite multi-agent regimens (Murphree, 1996). Intravitreal delivery risks extrascleral spread. Optimizing topotecan-carboplatin combinations lacks randomized data.
Route Selection Variability
Ophthalmic artery versus intravitreal routes vary in efficacy by tumor group, with inconsistent globe salvage (Yamane et al., 2004). Pediatric catheterization risks stroke in 5% of procedures. Standardization across ages is absent (Fabian et al., 2018).
Essential Papers
Retinoblastoma
Helen Dimaras, Kahaki Kimani, E Dimba et al. · 2012 · The Lancet · 639 citations
A Phase I/II Study of Direct Intraarterial (Ophthalmic Artery) Chemotherapy with Melphalan for Intraocular Retinoblastoma
David H. Abramson, Ira J. Dunkel, Scott E. Brodie et al. · 2008 · Ophthalmology · 475 citations
Chemotherapy Plus Local Treatment in the Management of Intraocular Retinoblastoma
A. Linn Murphree · 1996 · Archives of Ophthalmology · 469 citations
Thermochemotherapy is successful primary treatment for Reese-Ellsworth group 1 and 2 retinoblastomas. For larger tumors in the absence of vitreous or extensive subretinal seeding, 3 cycles of chemo...
Intra-arterial Chemotherapy for the Management of Retinoblastoma
Y. Pierre Gobin · 2011 · Archives of Ophthalmology · 428 citations
Our experience suggests that intra-arterial chemotherapy is safe and effective in the treatment of advanced intraocular retinoblastoma.
Chemotherapy With Focal Therapy Can Cure Intraocular Retinoblastoma Without Radiotherapy
Brenda L. Gallie · 1996 · Archives of Ophthalmology · 415 citations
This pilot study suggests that most retinoblastomas are curable by combining chemotherapy with cyclosporine therapy, laser therapy, and cryotherapy, without requiring external beam radiotherapy. We...
Uveal melanoma: epidemiology, etiology, and treatment of primary disease
Benjamin A. Krantz, Nikita Dave, Kimberly M. Komatsubara et al. · 2017 · Clinical ophthalmology · 387 citations
Uveal melanoma (UM) is the most common intraocular malignancy and arises from melanocytes in the iris, ciliary body, or choroid. Early diagnosis and local treatment is crucial, as survival correlat...
The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma
E. Rand Simpson, Brenda L. Gallie, Normand Laperrierre et al. · 2013 · Brachytherapy · 328 citations
Reading Guide
Foundational Papers
Start with Abramson et al. (2008, 475 citations) for phase I/II intra-arterial melphalan trial establishing 70% salvage; then Murphree (1996, 469 citations) on chemoreduction plus focal therapy for seeding control.
Recent Advances
Fabian et al. (2018, 243 citations) updates management integrating intra-arterial approaches; Simpson et al. (2013, 328 citations) on brachytherapy complements for residual disease.
Core Methods
Ophthalmic artery catheterization (Yamane et al., 2004); melphalan dosing 3-5 mg per cycle (Abramson et al., 2008); Reese-Ellsworth grouping for stratification (Murphree, 1996).
How PapersFlow Helps You Research Intraocular Chemotherapy for Retinoblastoma
Discover & Search
Research Agent uses searchPapers('intra-arterial melphalan retinoblastoma toxicity') to retrieve Abramson et al. (2008), then citationGraph to map 475 citing papers, and findSimilarPapers for topotecan studies. exaSearch uncovers phase II trials on vitreous seeds.
Analyze & Verify
Analysis Agent applies readPaperContent on Abramson et al. (2008) to extract salvage rates, verifyResponse with CoVe against 10 similar trials, and runPythonAnalysis to plot toxicity incidence from tables using pandas. GRADE grading scores evidence as moderate for globe salvage endpoints.
Synthesize & Write
Synthesis Agent detects gaps in randomized intravitreal data via gap detection, flags contradictions between Gobin (2011) and Murphree (1996) on seeding control, then Writing Agent uses latexEditText for methods section, latexSyncCitations for 20-paper bibliography, and latexCompile for manuscript PDF. exportMermaid generates toxicity profile flowcharts.
Use Cases
"Compare toxicity rates of melphalan vs topotecan in retinoblastoma trials"
Research Agent → searchPapers + citationGraph → Analysis Agent → readPaperContent (Abramson 2008, Gobin 2011) → runPythonAnalysis (pandas meta-analysis of rates) → CSV export of 95% CI comparisons.
"Draft review on intra-arterial chemotherapy protocols"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro + results) → latexSyncCitations (Gallie 1996 et al.) → latexCompile → PDF with embedded salvage rate figures.
"Find code for retinoblastoma survival modeling"
Research Agent → paperExtractUrls (Fabian 2018) → paperFindGithubRepo → githubRepoInspect (Kaplan-Meier scripts) → runPythonAnalysis sandbox tests R repo on trial data.
Automated Workflows
Deep Research workflow scans 50+ papers on melphalan delivery, chains searchPapers → citationGraph → GRADE grading, outputs structured report on salvage rates by group. DeepScan applies 7-step CoVe to verify toxicity claims from Yamane et al. (2004), with checkpoints on trial heterogeneity. Theorizer generates hypotheses on multi-agent synergies from Gallie (1996) and Abramson (2008) abstracts.
Frequently Asked Questions
What defines intraocular chemotherapy for retinoblastoma?
Delivery of melphalan, topotecan, or carboplatin directly into the vitreous or ophthalmic artery to target seeds and advanced intraocular tumors (Abramson et al., 2008).
What are main methods used?
Intra-arterial infusion via catheterization (Yamane et al., 2004) or intravitreal injection post-vitrectomy, combined with focal laser therapy (Gallie, 1996).
What are key papers?
Abramson et al. (2008, 475 citations) on phase I/II melphalan trial; Gobin (2011, 428 citations) on safety; Dimaras et al. (2012, 639 citations) comprehensive review.
What open problems exist?
Lack of randomized trials for route comparison, long-term neurotoxicity data, and protocols for bilateral group E disease (Fabian et al., 2018).
Research Ocular Oncology and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Intraocular Chemotherapy for Retinoblastoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Ocular Oncology and Treatments Research Guide